Life Matters Israel is a privately held company headquartered in Rehovot, Israel.
Life Matters Israel is a pre-clinical-stage biopharmaceutical company dedicated to significantly improving the lives of people with cystic fibrosis (CF).
At Life Matters we develop New Modality to fight resistant bacteria which are often inhabitant the CF patient’s lungs, by signaling the bacteria to remain in the planktonic mode rather than enter into the biofilm mode. This results in a much more treatable infection, leading to an improvement of how this disease is treated.
Morbidity & mortality in chronic lung infections are often due to biofilm associated P. aeruginosa. By eliminating the bacterial biofilm, we enable the innate immune system to eradicate the infection, improve the quality of life and prolong the life-span of CF patients, so that patients can live fuller lives
Our small molecules have superiority upon common traditional antibiotics since they do not possess any selection pressure towards the bacteria, a resistant creating mechanism which emphasis the resistant strains. Moreover, our compounds have a broad activity against various gram negative and positive pathogens.
Our lead API, IBF-2 is a first-of-its-kind compound with an innovative mechanism of action, can attenuate the biofilm mode of growth, a crucial phenotype allowing bacteria to survive despite environmental stresses such as antibacterial agents or the host immune system cell.
At Life Matters we are thinking out of the box, in order to provide a much better treatment and hope to patients. For this mission we recruited high skilled and well experienced personnel with exclusive records in drug development, lung disorders specialists and infectious diseases experts.